Kinneret Savitsky - BIOLINE RX Insider

  

CEO, Director

Dr. Kinneret Savitsky will no longer serve as Chief Executive Officer at BioLine Rx Ltd effective October 10 2016. She has held this role since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Age: 48  CEO Since 2010      
972 2 548 9100  http://www.biolinerx.com

Other Appointments

BioLineRx LtdBioLineRx Ltd NasdaqCEO
BioLineRx LtdBioLineRx Ltd Tel AvivCEO
Kinneret Savitsky EducationSavitsky holds a BS degree in Biology from The Hebrew University of Jerusalem, a MS degree in Human Genetics and a Doctorate of Science degree in Human Genetics, both from TelAviv University.

Management Efficiency

The company has return on total asset (ROA) of (39.95) % which means that it has lost $39.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (77.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 44.85 K in total debt. BIOLINE RX LTD has Current Ratio of 3.83 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Filter Other Executives

Position
Tenure
Industry
Click to run this filter
Filter Other Insiders
 
Showing few of many executives

CEO Since

Nils AndersenAP M
2012
Michael CorbatCitigroup Inc
2012
Allan ObermanTeva Pharmaceutical Industries
2012
Takashi NagashimaKDDI Corp
N/A
Francisco SilvaCitigroup Inc
N/A
James CowlesCitigroup Inc
2013
Morten EngelstoftAP M
2014
Zion KenanBank Hapoalim BM
2009
Eliyahu CohenBank Hapoalim BM
2011
Timothy MayopoulosFederal National Mortgage Assoc
2012
Claus HemmingsenAP M
2007
Shimon GalBank Hapoalim BM
2013
Ron WekslerBank Hapoalim BM
2013
Judith VardiTeva Pharmaceutical Industries
2012
Anat LevinBank Hapoalim BM
2010
William MillsCitigroup Inc
2013
Tsahi CohenBank Hapoalim BM
2012
James ForeseCitigroup Inc
2013
Jakob ThomasenAP M
2009
Orith LererBank Hapoalim BM
2012
Carlo NotaristefaniTeva Pharmaceutical Industries
2012

Entity Summary

Kinneret Savitsky Ph.D., 44Chief Exec. Officer327.00KN/AMr. Philip A. Serlin CPA, MBA, 51Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Member of Investment Monitoring Committee271.00KN/AProf. Moshe Phillip M.D., 57VP of Medical Affairs, Sr. Clinical Advisor and Member of Scientific Advisory Board291.00KN/ADr. Leah Klapper Ph.D., 47Gen. Mang. of BioLine Innovations Jerusalem237.00KN/A Raziel Fried, Treasurer and Member of Investment Monitoring CommitteeN/AN/ABIOLINE RX LTD (BLNEF) is traded on OTC Market in USA. It is located in , except where noted. and employs 52 people.
NameBIOLINE RX LTD
InstrumentUSA Stock
ExchangeOTC Market
ISINIL0011015182
Macroaxis Advice
CurrencyUSD - US Dollar
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BIOLINE RX LTD to your portfolio
Top Management
BIOLINE RX LTD Leadership Team
Jacob Friedman, Director, MBA
Nurit Benjamini, Director, MBA
Raphael Hofstein, Director
Mali Zeevi, Director, CPA
Philip Serlin, COO
Aharon Schwartz, Chairman
Kinneret Savitsky, CEO
Moshe Phillip, President, Ph.D
Merril Gersten, Executive
David Malek, President
Leah Klapper, Executive
Michael Anghel, Director, MBA
Avraham Molcho, Director, MBA
Sandra Panem, Director, Ph.D
Stock Performance
BIOLINE RX Performance Indicators